Founded in 2007, Fabentech is a private, clinical-stage biotech focused on biodefense and pandemic preparedness. Its core asset is the FabShield® platform for generating polyclonal antibody fragment therapies against lethal biological agents. The company has a diversified pipeline targeting toxins and viruses, with one product (Ricimed®) approved, another in Phase 2 for COVID-19, and several earlier-stage programs backed by European and French defense agencies. Fabentech operates as a specialized contractor for government and public health preparedness markets.
FabShield® platform for the production of highly purified polyclonal antibody fragments designed to broadly neutralize viruses and toxins.
Funding History
1
Total raised:$500K
Grant$500KFrench Tech Grant
Opportunities
The growing global focus on pandemic preparedness and biodefense sovereignty, particularly in the EU, creates significant funding and procurement opportunities.
The FabShield® platform's adaptability offers a potential rapid-response solution for future 'Disease X' outbreaks, positioning the company as a key partner for government stockpiling initiatives.
Approval of Ricimed® opens the door to initial revenue and validates the platform for follow-on toxin programs.
Risk Factors
High dependency on government funding and procurement, which is subject to political and budgetary shifts.
The inherent difficulty of conducting clinical trials for rare biotoxin exposures and the regulatory challenges of the 'Animal Rule.' A potentially limited total addressable market focused on government stockpiles rather than broad commercial sales.
Competitive Landscape
Fabentech competes with other biodefense-focused biotechs (e.g., Emergent BioSolutions, Ology Bioservices) and large pharma with government contracting divisions. Its key differentiation is the FabShield® polyclonal antibody fragment platform, which offers a potentially broader response against variants compared to monoclonal antibodies. Competition also comes from vaccine developers and small-molecule antiviral researchers for pandemic preparedness contracts.
